Experts at the European Respiratory Society (ERS) Congress 2025 highlight threats to scientific integrity from misinformation ...

Fintel reports that on September 29, 2025, RBC Capital reiterated coverage of Boston Scientific (NYSE:BSX) with a Outperform ...

Metabolic dysfunction–associated steatotic liver disease (MASLD) has become the leading cause of chronic liver disease in pediatric populations, reflecting ...

Direct-to-consumer devices promising pain relief are flooding the market. Is there enough evidence to recommend these devices to patients with chronic pain?

An executive order issued by the Trump Administration last month declares that NASA will now operate as an intelligence and ...

Somerlot v. Jung, strengthens the enforceability of forum-selection clauses in contracts with implications beyond the medical ...

Making a noteworthy insider sell on September 24, DAVID THOMAS HULL III, President at Kewaunee Scientific (NASDAQ: KEQU), is reported in the latest SEC filing.

Prime Medicine has surged over 130% in three months, driven by pipeline progress and visibility from recent scientific ...

DAVID THOMAS HULL III, President at Kewaunee Scientific (KEQU) , executed a substantial insider sell on September 22, according to an SEC filing. What Happened: A Form 4 filing from the U.S.

Some AI chatbots rely on flawed research from retracted scientific papers to answer questions, according to recent studies.